This NDC is on FDA's drug shortage list (posted Jul 14, 2023)
Reported reason: Shortage of an active ingredient
Product Information
LISDEXAMFETAMINE 70 MG CAPSULE is a generic product labeled by Elite Laboratories, Inc., priced at $2.6753 per EA under NDC 64850055601. Its NADAC has been published 74 times since May 7, 2025.
FDA first approved this application on Nov 15, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
70 mg/1
Manufacturer
Elite Laboratories, Inc.NDC
64850055601
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA218604FDA Approved
11/15/2024
TE Code
AB
On Market Since
11/15/2024
Pharmacological Classes
Price Statistics
The NADAC for LISDEXAMFETAMINE 70 MG CAPSULE has been published 74 times since May 7, 2025, and over the history we have for it it has declined 51.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6753 per EA |
|---|---|
| All-time high | $5.4942 (May 14, 2025) |
| All-time low | $2.6753 (Sep 23, 2026) |
| 52-week high | $3.3495 |
| 52-week low | $2.6753 |
| Median price | $3.0537 |
| Average price | $3.3733 |
| Largest weekly change | -16.8% (Jun 18, 2025) |
| Weeks tracked | 74 |
| Tracking since | May 7, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Elite Laboratories, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lisdexamfetamine dimesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LISDEXAMFETAMINE 70 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LISDEXAMFETAMINE 70 MG CAPSULE, manufactured by Elite Laboratories, Inc., is $2.6753 per EA (NDC 64850055601), effective Sep 30, 2026.
How has the price of LISDEXAMFETAMINE 70 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for LISDEXAMFETAMINE 70 MG CAPSULE has declined 51.3%. It has been tracked across 74 weekly CMS publications since May 7, 2025.
What are the highest and lowest recorded NADAC prices for LISDEXAMFETAMINE 70 MG CAPSULE?
Since May 7, 2025, the NADAC for LISDEXAMFETAMINE 70 MG CAPSULE has ranged from a low of $2.6753 (Sep 23, 2026) to a high of $5.4942 (May 14, 2025), with a median of $3.0537 per EA.
Are there cheaper alternatives to LISDEXAMFETAMINE 70 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LISDEXAMFETAMINE 70 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LISDEXAMFETAMINE 70 MG CAPSULE?
LISDEXAMFETAMINE 70 MG CAPSULE (NDC 64850055601) is labeled by Elite Laboratories, Inc., and CMS classifies it as a generic product.
Is LISDEXAMFETAMINE 70 MG CAPSULE in shortage?
Yes — NDC 64850055601 is currently listed in FDA's drug shortage database (posted Jul 14, 2023). Reported reason: Shortage of an active ingredient.